Normal Growth of Nephrotic Children during Long‐term Alternate‐day Prednisone Therapy

Abstract
Statural growth has been evaluated in 20 prepubertal nephrotic children who received alternate‐day prednisone therapy for a year at least. Bone age was assessed in 16 of these children after 1‐4 years of therapy. During the follow‐up 12 children showed variations in height standard deviation score (SDs) below 0.5, 7 gained more than 0.5 SDs and 1 lost 0.5 SDs. Bone age fell within the normal range for chronological age in all the children studied. On the while alternate‐day prednisone therapy does not affect statural growth and bone maturation of children with lipoid nephrosis.